Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DS 5670

Next Previous
X
Search
Drug Profile

DS 5670

Alternative Names: Coronavirus vaccine - Daiichi Sankyo; DS-5670; DS-5670a

Latest Information Update: 30 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 05 Aug 2023 Daiichi Sankyo completes a phase II trial in COVID-2019 infections (In adults, Prevention) in Japan (IM) (jRCT2071210086)
  • 03 Feb 2023 Phase-III clinical trials in COVID-2019 infections (Prevention, In adolescents) in Japan prior to February 2023 (IM) (jRCT2031220400)
  • 03 Feb 2023 Daiichi Sankyo Company plans a phase II/III trial for COVID-2019 infections (In children, Prevention) in Japan (IM) (jRCT2031220399) (Daiichi Sankyo Company pipeline, February 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top